Victory Capital Management
NGM

Victory Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Victory Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-79,048
Closed -$974K – 3427
2020
Q1 		$974K Buy
79,048
+35,700
+82% +$583K ﹤0.01% 1858
2019
Q4 		$802K Sell
43,348
-273,968
-86% -$4.01M ﹤0.01% 1810
2019
Q3 		$4.39M Buy
317,316
+189,566
+148% +$2.85M 0.01% 1197
2019
Q2 		$1.87M Buy
+127,750
New +$1.87M ﹤0.01% 1155

Other funds holding NGM

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.49B AUM 18.72% 1-Year Est. Return

Victory Capital Management's NGM Position: Q2 2020 in Review

Victory Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2020, closing a stake of 79,048 shares — an estimated $974K sold.

Victory Capital Management first reported a position in NGM in Q2 2019 and held it in 4 quarters. The position peaked at $4.39M in Q3 2019. 84 funds tracked by Wall St. Rank hold NGM as of Q2 2020.

  • Victory Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 79,048 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $974K.
  • Victory Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • Victory Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $4.39M in Q3 2019.
  • 84 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.